Liposomal all-trans retinoic acid boosts anti-tumor immunity of radiotherapy via mitigating cancer stemness and remedying tumor microenvironment

IF 10.5 1区 医学 Q1 CHEMISTRY, MULTIDISCIPLINARY
Huilan He , Yun Zheng , Jinlong Ji , Chunlian Ye , Yu Sun , Yuwei Peng , Ying Zhang , Zhiyuan Zhong
{"title":"Liposomal all-trans retinoic acid boosts anti-tumor immunity of radiotherapy via mitigating cancer stemness and remedying tumor microenvironment","authors":"Huilan He ,&nbsp;Yun Zheng ,&nbsp;Jinlong Ji ,&nbsp;Chunlian Ye ,&nbsp;Yu Sun ,&nbsp;Yuwei Peng ,&nbsp;Ying Zhang ,&nbsp;Zhiyuan Zhong","doi":"10.1016/j.jconrel.2025.113995","DOIUrl":null,"url":null,"abstract":"<div><div>Radiotherapy (RT) induces immunogenic cell death but also promotes immunosuppression, cancer stemness and immune evasion, thus compromising anti-tumor immune response and leading to cancer recurrence and metastasis. Here, we developed liposomal all-trans retinoic acid nanoparticles (LATRA) to simultaneously mitigate cancer stemness and remedy suppressive tumor microenvironment, which on one hand decreases tumorigenicity and sensitizes tumors to RT and on the other hand stimulates dendritic cell maturation and reprograms macrophages toward a pro-inflammatory M1 phenotype. In murine colorectal tumor model, RT combined with LATRA essentially reduces tumor burden, prevents recurrence and induces a durable immune response with memory effects. Notably, LATRA effectively eradicates residual tumor cells in post-surgery 4T1 breast tumor model, avoiding tumor relapse and lung metastasis. Liposomal all-trans retinoic acid offers a new and promising strategy to empower RT-induced anti-tumor immunity.</div></div>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":"385 ","pages":"Article 113995"},"PeriodicalIF":10.5000,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Controlled Release","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0168365925006169","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0

Abstract

Radiotherapy (RT) induces immunogenic cell death but also promotes immunosuppression, cancer stemness and immune evasion, thus compromising anti-tumor immune response and leading to cancer recurrence and metastasis. Here, we developed liposomal all-trans retinoic acid nanoparticles (LATRA) to simultaneously mitigate cancer stemness and remedy suppressive tumor microenvironment, which on one hand decreases tumorigenicity and sensitizes tumors to RT and on the other hand stimulates dendritic cell maturation and reprograms macrophages toward a pro-inflammatory M1 phenotype. In murine colorectal tumor model, RT combined with LATRA essentially reduces tumor burden, prevents recurrence and induces a durable immune response with memory effects. Notably, LATRA effectively eradicates residual tumor cells in post-surgery 4T1 breast tumor model, avoiding tumor relapse and lung metastasis. Liposomal all-trans retinoic acid offers a new and promising strategy to empower RT-induced anti-tumor immunity.

Abstract Image

Abstract Image

脂质体全反式维甲酸通过缓解肿瘤干细胞和修复肿瘤微环境来增强放疗的抗肿瘤免疫
放射治疗(RT)诱导免疫原性细胞死亡,但也促进免疫抑制、肿瘤干性和免疫逃避,从而损害抗肿瘤免疫应答,导致癌症复发和转移。在这里,我们开发了脂质体全反式维甲酸纳米颗粒(LATRA),以同时减轻癌症干性和改善抑制肿瘤微环境,一方面降低肿瘤致瘤性并使肿瘤对RT敏感,另一方面刺激树突状细胞成熟并将巨噬细胞重编程为促炎M1表型。在小鼠结直肠肿瘤模型中,RT联合LATRA从本质上减轻了肿瘤负担,防止复发,并诱导具有记忆效应的持久免疫反应。值得注意的是,LATRA在术后4 T1乳腺肿瘤模型中有效根除残留肿瘤细胞,避免肿瘤复发和肺转移。脂质体全反式维甲酸为增强放射治疗诱导的抗肿瘤免疫提供了一种新的有前途的策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Controlled Release
Journal of Controlled Release 医学-化学综合
CiteScore
18.50
自引率
5.60%
发文量
700
审稿时长
39 days
期刊介绍: The Journal of Controlled Release (JCR) proudly serves as the Official Journal of the Controlled Release Society and the Japan Society of Drug Delivery System. Dedicated to the broad field of delivery science and technology, JCR publishes high-quality research articles covering drug delivery systems and all facets of formulations. This includes the physicochemical and biological properties of drugs, design and characterization of dosage forms, release mechanisms, in vivo testing, and formulation research and development across pharmaceutical, diagnostic, agricultural, environmental, cosmetic, and food industries. Priority is given to manuscripts that contribute to the fundamental understanding of principles or demonstrate the advantages of novel technologies in terms of safety and efficacy over current clinical standards. JCR strives to be a leading platform for advancements in delivery science and technology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信